This new investment coincides with increased management participation in the equity of KLS Partners, it said.
Kurma has also launched its second fund, Kurma Biofund II, the first venture capital fund dedicated to financing innovation with a diversified strategy and significant exposure to rare diseases, sponsored by Idinvest Partners alongside CDC Entreprises (BPIfrance), GSK and NEA.
Christophe Bavière, CEO of Idinvest Partners, said, “This investment comes after ten years of our teams working together. When Thierry Laugel and Rémi Droller, two former Idinvest Partners employees, founded KLS Partners in 2010, they continued providing insight on Idinvest Partners’ health sector investments.
“We are delighted to be able to pursue this partnership, which rounds out Idinvest’s own ample expertise in digital and cleantech.”
Founded in July 2009, KLS Partners provides venture capital, development capital and technology transfer in the life sciences space, including biotechnologies, health, nutrition, environmental sciences.
Founded as AGF Private Equity in 1997, Idinvest Partners was formerly part of the Allianz Group until 2010 when it joined forces with IDI Group to become independent.
It has €4bn under management. Earlier this month the firm smashed its €250m target by raking in €281m for its latest senior debt vehicle.
Copyright © 2013 AltAssets